New hires:
AbelsonTaylor Group, the parent company for the firm’s various healthcare businesses, hired Lane Degenhart as VP, account director.
Boundless Life Sciences Group, which finished just outside of the 2023 MM+M Agency 100 list, hired Sid DeSousa as CEO of Boundless Medical Communications, a newly created U.S. based firm.
BioNTech hired Novartis exec Annemarie Hanekamp as chief commercial officer, effective July 1.
Endeavor BioMedicines named Enoch Kariuki, PharmD as its president and Vishaal Turakhia as its CFO.
Independent healthcare marketing agency The Considered appointed three new VPs: Chelsea McCloskey-Lambert, Vini Watson and Nick Greenwood.
AffyImmune Therapeutics appointed Matt Britz as CEO and Pete Gelinas as SVP of CMC.
Rob Sutton joined Wondr Health as its CFO.
Golin Health named Erin Patton as associate MD.
Dallas-based private equity firm Trinity Hunt Partners formed life sciences platform Supreme Group and appointed former Medical Knowledge Group executive Tom Donnelly as CEO.
Folx Health named Greg Sottolano as chief people officer.
North East life sciences and pharmaceutical marketing and PR agency Ramarketing named Melissa Pattinson as its CFO.
CJ Biomaterials, a division of South Korea-based CJ CheilJedang, named Harry Jang as CEO.
Solu Therapeutics added Michael Boretti, PhD as chief business officer.
Executive elevations:
MSL U.S. elevated Bailey Pescatore to MD of its health practice.
MapLight Therapeutics announced Vishwas Setia will succeed Jonathan Gillis as CFO, while he transitions to chief administrative and accounting officer.
Clinical research organization Parexel announced its chief operating and growth officer Peyton Howell will succeed Jamie Macdonald as chief operating officer on May 15.
Virgo Health promoted Jaimee Reggio to MD of U.S. operations, a newly created role.
Public affairs and political consulting firm SKDK made a series of promotions.
Radiopharma company Lantheus promoted Amanda Morgan to chief commercial officer and elevated her to the executive team, effective March 25.
Intra-Cellular Therapies unveiled a series of executive appointments and leadership changes.
Board appointments:
Chip Romp, the former head of commercial at Seagen, joined the board of directors at Minds + Assembly, a 2023 MM+M Agency 100 honoree.
Amylyx Pharmaceuticals added Bernhardt Zeiher, MD, FCCP, FACP to its board of directors.
FundaMental Pharma added Dr. Lorenz Mayr as a non-executive director.
PatientPoint’s chief client officer Linda Ruschau was named co-chair of the Point Of Care Marketing Association.
Charm Therapeutics announced the foundation of its scientific advisory board.
Preclinical-stage company S. M. Discovery Group named Dr. Zsuzsanna Devecseri, MD, MBA to its board of directors.
Rapport Therapeutics named John Maraganore to its board of directors.
D3 Bio appointed Dr. Antoine Yver as an independent board member.
Repligen added Maggie A. Pax to its board of directors.
Departures:
Biogen’s chief medical officer Maha Radhakrishnan left the company after four years earlier this month.
Bayer eliminated nearly half of its executive positions as part of a major organizational overhaul.
Y-mAbs Therapeutics announced that Bo Kruse has resigned as CFO and will stay on until a successor is named. Kruse will then continue as a non-executive employee from the time his successor joins through July 31.
